| abstract |
The present invention includes IL-17, including adenosine production promoters, Th2 cytokine inhibitors such as IL-4, IL-5, IL-9, IL-13, or signaling inhibitors thereof, and drugs that inhibit or inhibit the production of uric acid. It relates to a combination preparation for the prevention or treatment of inflammatory diseases mediated by. In addition, the present invention is a non-eosinophilic or neutrophil respiratory inflammatory disease caused or aggravated by IL-17 by incorporating adenosine production promoters, Th2 cytokine inhibitors or signaling inhibitors thereof, and drugs that inhibit or inhibit the production of uric acid, Lung cancer, gastric cancer, and colon cancer caused by complications of gastrointestinal disease, vascular / metabolic disease, skin disease, bone joint disease, cerebral nerve disease, and neutrophil inflammation caused by IL-17 It relates to a method of preventing or treating. |